Lynda M. Grinsted

Oncology R&D
Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinoma.

A quantitative model-based approach for adavosertib dose selection in patients with uterine serous carcinoma.

Journal: British journal of clinical pharmacology

Published: September 18, 2024

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

Journal: Future oncology (London, England)

Published: September 16, 2024

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.

Journal: The New England journal of medicine

Published: May 31, 2023

Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions.

Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions.

Journal: Pharmaceutical statistics

Published: June 10, 2022

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.

Journal: British journal of cancer

Published: April 23, 2018

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial.

Journal: Lancet (London, England)

Published: October 19, 2016

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy.

Journal: Cancer

Published: November 19, 2015

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

Journal: The Lancet. Oncology

Published: December 04, 2012

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma.

Journal: British journal of cancer

Published: September 01, 2012

Showing 1-9 of 9

Last Updated: 09/26/2026